Reticulum cell sarcoma

Summary

Reticulum cell sarcoma (MONDO:0009975) is a cancer with 1 GWAS associations across 2 studies. A subtype of lymphatic system cancer — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Prevalence: <1 / 1 000 000 (Europe) [Orphanet-validated]
• GWAS associations: 1

Clinical features

Epidemiology

Prevalence records

1 prevalence record(s), Orphanet:

Type	Class	Value	Geography	Validation
Annual incidence	<1 / 1 000 000		Europe	Validated

Identifiers

Disease identifiers

Field	Value
Canonical name	reticulum cell sarcoma
Mondo ID	MONDO:0009975
EFO	EFO:0005287
OMIM	267730
Orphanet	86900
DOID	DOID:8538
NCIT	C27824
SNOMED CT	373168002
UMLS	C0024302
MedGen	44224
GARD	0016765
MedDRA	10038804
Is cancer (heuristic)	yes

Also known as: interdigitating cell sarcoma · large-cell Lymphomas · reticular cell sarcoma · reticulosarcoma · Reticulum cell sarcoma · reticulum cell sarcoma · sarcoma of reticular cell

Data availability: 1 GWAS association (2 studies).

Disease family

This is a subtype of lymphatic system cancer. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › immune system cancer › lymphatic system cancer › reticulum cell sarcoma

Related subtypes (3): lymph node cancer, lymphosarcoma, spleen cancer

Genetics & variants

GWAS landscape

1 GWAS associations across 2 studies. Top hits map to 1 distinct genes (as reported by GWAS).

Top associations by p-value

rsID	p-value	Gene	Risk allele	Odds ratio
rs7071908	3e-10	ARID5B	?

Top studies (by case count)

Study	Lead author	Year	Cases	Controls	Title
GCST90481539	Verma A	2024	1,157	449,859	Diversity and scale: Genetic architecture of 2068 traits in the VA Million Veteran Program.
GCST90651266	Liu TY	2025	307	235,192	Diversity and longitudinal records: Genetic architecture of disease associations and polygenic risk in the Taiwanese Han population.

Variant details and genetic-evidence tiers

Tier distribution (top 50 variants)

Tier	Variants
Tier 1: coding	0
Tier 2: splice/UTR	0
Tier 3: regulatory	0
Tier 4: intronic/intergenic	1

MAF distribution

Bucket	Variants
common (>=0.05)	1
low_freq (0.01-0.05)	0
rare (<0.01)	0
unknown	0

Functional consequences

Consequence	Count
intron_variant	1

Top variants

rsID	Chr	Pos	Alleles	MAF	Consequence	Gene	p-value	Tier
rs7071908	10	61935039	C>A,T	0.05	intron_variant	ARID5B	3e-10	Tier 4: intronic/intergenic

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.